Structure posts early oral obesity data, delays larger readout

Structure posts early oral obesity data, delays larger readout

Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks. | Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks.

Alzheimer's disease - The Lancet

Multimodal population brain imaging in the UK Biobank prospective epidemiological study

IJMS, Free Full-Text

Frontiers Influence of High Energy Diet and Polygenic Predisposition for Obesity on Postpartum Health in Rat Dams

Frontiers Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

Structure tumbles as oral GLP-1 data underwhelm investors

Aberrant olfactory network functional connectivity in people with olfactory dysfunction following COVID-19 infection: an exploratory, observational study - eClinicalMedicine

Antioxidants, Free Full-Text

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis: Molecular Therapy Methods & Clinical Development

T cell–mediated regulation of the microbiota protects against obesity

Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor: Trends in Endocrinology & Metabolism

Frontiers Neuroinflammation and White Matter Alterations in Obesity Assessed by Diffusion Basis Spectrum Imaging

Alzheimer disease Nature Reviews Disease Primers

Frontiers Obesity and renal disease: Benefits of bariatric surgery